| Literature DB >> 1095122 |
E Engelsman, J C Heuson, J Blonk Van Der Wijst, A Drochmans, H Maass, F Cheix, L G Sobrinho, H Nowakowski.
Abstract
L-Dopa lowers plasma prolactin levels, and there have been reports that patients with advanced breast cancer have been successfully treated with L-dopa. To test the potential value of L-dopa in this disease a randomized clinical trial of L-dopa and nafoxidine (as the reference compound) was conducted in postmenopausal women with advanced breast cancer. Objective remissions were obtained in sever out of 36 patients (19%) treated with nafoxidine but in none out of 40 patients treated with L-dopa. L-Dopa in the dose schedule used seems to be ineffective in advanced breast cancer.Entities:
Mesh：
Substances：
Year: 1975 PMID： 1095122 PMCID： PMC1673916 DOI： 10.1136/bmj.2.5973.714
Source DB: PubMed Journal: Br Med J ISSN： 0007-1447